Coeptis Therapeutics (COEP)
Market Price (3/30/2026): $10.68 | Market Cap: $57.6 MilSector: Health Care | Industry: Biotechnology
Coeptis Therapeutics (COEP)
Market Price (3/30/2026): $10.68Market Cap: $57.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11% | Weak multi-year price returns3Y Excs Rtn is -123% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -957% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -74% | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 89% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -631%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -631% | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -23% | ||
| Key risksCOEP key risks include [1] significant financial and regulatory instability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -74% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Weak multi-year price returns3Y Excs Rtn is -123% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -957% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 89% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -631%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -631% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -23% |
| Key risksCOEP key risks include [1] significant financial and regulatory instability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Coeptis Therapeutics (COEP) stock has lost about 45% since 11/30/2025 because of the following key factors:
1. Strategic Shift to Dogecoin Mining and Biopharma Spin-out Created Uncertainty.
Coeptis Therapeutics announced a definitive merger agreement with Z Squared Inc., a Dogecoin mining company. This transaction, which gained shareholder approval on January 30, 2026, involves Coeptis spinning out its biopharmaceutical operations to become primarily a publicly-traded, Dogecoin-focused mining company, subsequently rebranding as Z Squared, Inc.. This significant shift from a biopharmaceutical focus to cryptocurrency mining likely caused investor apprehension and a re-evaluation of the company's future direction. Existing Coeptis shareholders are expected to retain 21% of the combined entity post-merger, and the biopharma spin-out is valued at an estimated $75 million to be distributed to them.
2. Persistent Unprofitability and Weak Financial Performance Drove Investor Skepticism.
Coeptis Therapeutics has continued to report substantial financial losses, contributing to investor skepticism. For the full year ended December 31, 2025, the company reported a net loss of $11.92 million, increasing its accumulated deficit to $109,953,728. The company's Q3 2025 results showed a negative diluted earnings per share (EPS) of -$0.58, an operating margin of -1043.2%, and a net profit margin of -1220.8%, highlighting ongoing operational inefficiencies and a significant lack of profitability. Additionally, auditors raised substantial doubt about the company's ability to continue as a going concern, emphasizing its heavy reliance on external financing.
Show more
1. Strategic Shift to Dogecoin Mining and Biopharma Spin-out Created Uncertainty.
Coeptis Therapeutics announced a definitive merger agreement with Z Squared Inc., a Dogecoin mining company. This transaction, which gained shareholder approval on January 30, 2026, involves Coeptis spinning out its biopharmaceutical operations to become primarily a publicly-traded, Dogecoin-focused mining company, subsequently rebranding as Z Squared, Inc.. This significant shift from a biopharmaceutical focus to cryptocurrency mining likely caused investor apprehension and a re-evaluation of the company's future direction. Existing Coeptis shareholders are expected to retain 21% of the combined entity post-merger, and the biopharma spin-out is valued at an estimated $75 million to be distributed to them.
2. Persistent Unprofitability and Weak Financial Performance Drove Investor Skepticism.
Coeptis Therapeutics has continued to report substantial financial losses, contributing to investor skepticism. For the full year ended December 31, 2025, the company reported a net loss of $11.92 million, increasing its accumulated deficit to $109,953,728. The company's Q3 2025 results showed a negative diluted earnings per share (EPS) of -$0.58, an operating margin of -1043.2%, and a net profit margin of -1220.8%, highlighting ongoing operational inefficiencies and a significant lack of profitability. Additionally, auditors raised substantial doubt about the company's ability to continue as a going concern, emphasizing its heavy reliance on external financing.
Show more
Stock Movement Drivers
Fundamental Drivers
The -43.0% change in COEP stock from 11/30/2025 to 3/29/2026 was primarily driven by a -76.2% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 18.73 | 10.68 | -43.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 172.1% |
| P/S Multiple | 177.4 | 42.3 | -76.2% |
| Shares Outstanding (Mil) | 5 | 5 | -12.1% |
| Cumulative Contribution | -43.0% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| COEP | -43.0% | |
| Market (SPY) | -5.3% | 37.5% |
| Sector (XLV) | -8.7% | 32.7% |
Fundamental Drivers
The -19.8% change in COEP stock from 8/31/2025 to 3/29/2026 was primarily driven by a -77.4% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.32 | 10.68 | -19.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 417.2% |
| P/S Multiple | 187.4 | 42.3 | -77.4% |
| Shares Outstanding (Mil) | 4 | 5 | -31.3% |
| Cumulative Contribution | -19.8% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| COEP | -19.8% | |
| Market (SPY) | 0.6% | 25.8% |
| Sector (XLV) | 5.2% | 23.2% |
Fundamental Drivers
The -0.7% change in COEP stock from 2/28/2025 to 3/29/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.75 | 10.68 | -0.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 42.3 | |
| Shares Outstanding (Mil) | 2 | 5 | -63.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| COEP | -0.7% | |
| Market (SPY) | 9.8% | 7.1% |
| Sector (XLV) | -2.1% | 10.1% |
Fundamental Drivers
The -67.6% change in COEP stock from 2/28/2023 to 3/29/2026 was primarily driven by a -81.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 33.00 | 10.68 | -67.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 1 | 0.0% |
| P/S Multiple | � | 42.3 | 0.0% |
| Shares Outstanding (Mil) | 1 | 5 | -81.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| COEP | -67.6% | |
| Market (SPY) | 69.4% | -1.3% |
| Sector (XLV) | 18.4% | 1.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| COEP Return | -2% | -85% | -49% | -65% | 159% | -23% | -95% |
| Peers Return | -33% | -38% | -29% | -55% | -48% | 8% | -93% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| COEP Win Rate | 58% | 67% | 33% | 42% | 50% | 0% | |
| Peers Win Rate | 31% | 44% | 44% | 36% | 50% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| COEP Max Drawdown | -4% | -90% | -51% | -99% | 0% | -27% | |
| Peers Max Drawdown | -40% | -52% | -49% | -60% | -61% | -24% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, AKTS, ALPS, DCOY, DFTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | COEP | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -93.7% | -25.4% |
| % Gain to Breakeven | 1491.2% | 34.1% |
| Time to Breakeven | 396 days | 464 days |
Compare to VRTX, AKTS, ALPS, DCOY, DFTX
In The Past
Coeptis Therapeutics's stock fell -93.7% during the 2022 Inflation Shock from a high on 10/28/2022. A -93.7% loss requires a 1491.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Coeptis Therapeutics (COEP)
Bull Horn Holdings Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was founded in 2018 and is based in Miami Beach, Florida.
AI Analysis | Feedback
A specialized private equity firm focused on acquiring sports, entertainment, or brand companies and taking them public.
AI Analysis | Feedback
nullAI Analysis | Feedback
Coeptis Therapeutics (symbol: COEP) is a biopharmaceutical company focused on the development of innovative therapies for cancer and other serious diseases. As a company primarily engaged in research and development, and with product candidates currently in clinical trials or earlier stages, Coeptis Therapeutics does not currently have major customers in the traditional sense of selling commercialized products or services to other companies or individuals.
AI Analysis | Feedback
nullAI Analysis | Feedback
Dave Mehalick, Chairman, President and Chief Executive Officer
Mr. Mehalick is a co-founder of Coeptis Therapeutics. He is a successful executive with over 30 years of experience across various industries including life sciences, technology, financial services, military contracting, entertainment, and consumer products. His career has involved deep immersion in mergers and acquisitions, corporate finance, C-Suite management, product development and licensing, partnerships, product commercialization, and corporate communications. Mr. Mehalick has assisted and managed several organizations toward successful investor monetization, resulting in billions of dollars in transactions and financings. He began his career in financial services, including investment banking, holding positions at firms such as First Union Capital Markets, Gruntal and Co., and Ferris Baker Watts. He was a founding partner in American Defense Systems, a military contractor that grew and went public on the AMEX stock exchange. Throughout his career, he has been involved in numerous similar situations in management or consultant roles to achieve strong returns for shareholders via acquisitions or public strategies. Coeptis itself went public following a SPAC transaction.
Brian Cogley, Chief Financial Officer
Mr. Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across various industries, including life sciences, pharmaceuticals, financial services, and manufacturing.
Christine Sheehy, VP of Compliance and Corporate Secretary
Ms. Sheehy is a pharmaceutical business leader with over 25 years of experience, including globally commercializing drug products and working in the development of targeted therapeutics, including cell and gene therapies.
Dan Yerace, Director and Vice President of Operations
Mr. Yerace is a co-founder of Coeptis Therapeutics. He has over ten to fifteen years of experience in the pharmaceutical industry and is a key strategist responsible for supply chain management, business development, portfolio management, and corporate strategy.
AI Analysis | Feedback
Key Risks to Coeptis Therapeutics (COEP)
- Risk of Nasdaq Delisting: Coeptis Therapeutics Holdings, Inc. has faced notification from Nasdaq regarding its non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Failure to achieve and maintain a closing bid price of at least $1.00 per share within the compliance period could lead to the delisting of the company's stock, significantly impacting its liquidity and ability to raise capital.
- Clinical Development and Regulatory Approval Risk: As a biopharmaceutical company focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases, Coeptis Therapeutics' success is heavily dependent on the successful completion of clinical trials and subsequent regulatory approvals from authorities such as the U.S. Food and Drug Administration (FDA). There is an inherent risk that the company's product candidates may fail clinical trials or not receive the necessary regulatory clearances, which would significantly impede its ability to commercialize products and generate revenue.
- Inability to Successfully Commercialize Products and Maintain Economic Viability: Coeptis Therapeutics' business model involves developing and expanding its product portfolio, often through in-license and out-license agreements and co-development relationships. A key risk is the potential inability to fully realize the anticipated benefits from these licensed assets or to establish an economically viable model from such deals. This also encompasses challenges in creating sustainable revenue streams from its therapeutic pipeline and its dual-track business model (which includes a revenue-generating AI technology platform) to reduce reliance on dilutive financing.
AI Analysis | Feedback
nullAI Analysis | Feedback
Coeptis Therapeutics (COEP) focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, with key products and platforms including SNAP-CAR, CD38-GEAR-NK (GEAR Cell Therapy Platform), and DVX201. The company also has a CD38-Diagnostic and a NexGenAI Affiliates Network platform, which offers AI-powered marketing software.
The addressable market for Coeptis Therapeutics' main products, primarily within the cell therapy space, is significant. The global cell therapy market is projected to grow from an estimated $5.88 billion in 2024 to $44.39 billion by 2034.
AI Analysis | Feedback
Coeptis Therapeutics (COEP) is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Its future revenue growth over the next 2-3 years is expected to be driven by several key factors:
- Advancement and Commercialization of CD38-GEAR-NK and CD38-Diagnostic: Coeptis is actively working to advance its CD38-GEAR-NK cell therapy and the CD38-Diagnostic, an in vitro screening tool. The CD38-GEAR-NK therapy, a natural killer (NK) cell-based therapy, is designed to support combination treatments with anti-CD38 monoclonal antibodies in cancers such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. The CD38-Diagnostic aims to identify patients most likely to benefit from anti-CD38 monoclonal antibody treatments. Successful clinical development and subsequent commercialization of these assets are expected to be significant revenue drivers.
- Development and Market Entry of SNAP-CAR Technology: The company is developing SNAP-CAR, a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh. This innovative platform has the potential to lead to new cell therapies for various cancers, and its progression into clinical trials and eventual market approval would contribute to future revenue growth.
- Progress of DVX201 and Allogeneic Cellular Immunotherapy Platforms: Coeptis' therapeutic portfolio includes assets licensed from Deverra Therapeutics, such as DVX201, a clinical-stage, unmodified natural killer cell therapy technology, and an allogeneic cellular immunotherapy platform. The successful development and potential commercialization of these advanced cell therapies represent further avenues for revenue generation.
- Revenue Generation from the NexGenAI Platform: Coeptis has adopted a dual-track business model that includes a revenue-generating AI technology platform called NexGenAI. This platform, which incorporates AI-powered marketing software and robotic process automation, is designed to generate revenue to support the company's therapeutic pipeline and reduce reliance on dilutive equity financing.
- Expansion into Autoimmune and Infectious Diseases: While a primary focus is oncology, Coeptis is developing innovative cell therapy platforms for autoimmune and infectious diseases. Successful diversification and commercialization of therapies in these additional disease areas would broaden the company's market reach and create new revenue streams beyond its current cancer-focused pipeline.
AI Analysis | Feedback
Share Repurchases
- Coeptis Therapeutics Holdings Inc. has maintained a 0% buyback yield over the last three to five years, indicating no share repurchases during this period.
Share Issuance
- In October 2022, Coeptis Therapeutics completed a merger with Bull Horn Holdings Corp., where Coeptis shareholders received equity in Bull Horn valued at $175 million.
- A 1-for-20 reverse stock split was executed on December 31, 2024, to ensure compliance with Nasdaq listing requirements and improve stock marketability.
- Shareholders have experienced substantial dilution in the past year, as of March 2026.
Inbound Investments
- Coeptis Therapeutics entered into a definitive merger agreement with Bull Horn Holdings Corp. in April 2022, which was completed in October 2022. This business combination provided Coeptis with access to capital to advance its product portfolio.
- As part of the merger, the equity of Coeptis was valued at $175 million.
Outbound Investments
- Coeptis has licensed assets from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy.
- The company licensed a universal, multi-antigen CAR technology (SNAP-CAR) from the University of Pittsburgh.
- Coeptis acquired an AI-powered marketing software and robotic process automation platform from NexGenAI Solutions Group, expanding its technology division to generate revenue and support its biopharmaceutical development.
Capital Expenditures
- Coeptis Therapeutics Inc. reported $0 in capital expenditures in Q1 2023.
- The company has shown a 0% average for Capital Expenditures to Operating Cash Flow (CapEx/OCF) over the past three and five years, indicating minimal capital expenditures.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Is Coeptis Therapeutics Stock Built to Withstand a Pullback? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to COEP.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 12.93 |
| Mkt Cap | 0.1 |
| Rev LTM | 1 |
| Op Inc LTM | -9 |
| FCF LTM | -7 |
| FCF 3Y Avg | -8 |
| CFO LTM | -7 |
| CFO 3Y Avg | -8 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.9% |
| Rev Chg 3Y Avg | 10.4% |
| Rev Chg Q | 9.5% |
| QoQ Delta Rev Chg LTM | 87.2% |
| Op Mgn LTM | -459.5% |
| Op Mgn 3Y Avg | 24.7% |
| QoQ Delta Op Mgn LTM | 860.0% |
| CFO/Rev LTM | -300.5% |
| CFO/Rev 3Y Avg | 20.5% |
| FCF/Rev LTM | -302.3% |
| FCF/Rev 3Y Avg | 17.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.1 |
| P/S | 25.7 |
| P/EBIT | -0.0 |
| P/E | -0.1 |
| P/CFO | -0.1 |
| Total Yield | -18.9% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -205.0% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -12.0% |
| 3M Rtn | -6.4% |
| 6M Rtn | 5.3% |
| 12M Rtn | 9.6% |
| 3Y Rtn | 12.1% |
| 1M Excs Rtn | -3.8% |
| 3M Excs Rtn | 1.7% |
| 6M Excs Rtn | 8.9% |
| 12M Excs Rtn | -2.1% |
| 3Y Excs Rtn | -49.7% |
Price Behavior
Price Behavior
| Market Price | $10.68 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 12/17/2020 | |
| Distance from 52W High | -43.2% | |
| 50 Days | 200 Days | |
| DMA Price | $12.29 | $13.11 |
| DMA Trend | up | down |
| Distance from DMA | -13.1% | -18.5% |
| 3M | 1YR | |
| Volatility | 74.6% | 88.6% |
| Downside Capture | 1.80 | 0.78 |
| Upside Capture | 206.67 | 105.42 |
| Correlation (SPY) | 39.4% | 8.5% |
COEP Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.97 | 3.27 | 3.15 | 1.69 | 0.30 | -1.80 |
| Up Beta | 2.82 | 4.77 | 4.26 | 2.53 | 0.26 | -0.22 |
| Down Beta | 5.68 | 2.89 | 2.63 | 1.35 | -0.24 | 6.58 |
| Up Capture | 365% | 236% | 173% | 143% | 59% | -5% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 10 | 18 | 27 | 54 | 119 | 352 |
| Down Capture | 391% | 337% | 358% | 170% | 75% | -30% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 11 | 23 | 34 | 70 | 129 | 381 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COEP | |
|---|---|---|---|---|
| COEP | 9.9% | 88.2% | 0.52 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 13.0% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 8.6% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 13.3% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 5.6% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 3.8% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 19.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COEP | |
|---|---|---|---|---|
| COEP | -44.5% | 1,612.8% | 0.43 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 1.0% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | -0.7% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 1.8% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 1.3% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 2.5% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 1.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COEP | |
|---|---|---|---|---|
| COEP | -25.6% | 1,571.9% | 0.42 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 1.0% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | -0.7% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 1.8% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 1.2% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 2.4% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 0.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/19/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/28/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/16/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/26/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/29/2023 | 10-K |
| 09/30/2022 | 02/14/2023 | S-1 |
| 06/30/2022 | 09/30/2022 | S-4/A |
| 03/31/2022 | 07/28/2022 | S-4/A |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.